AMG
33
-11
SHW
42
5
AES
47
4
FTI
61
5
DE
49
3
KMI
69
8
HCA
37
7
ROST
60
3
CRM
65
6
QRVO
16
-6
XYL
29
4
WBA
41
3
HCP
54
2
KO
44
2
NKE
36
2
CVX
25
14
ADP
57
2
FITB
36
3
HRB
40
3
ADI
54
4
AMG
33
-11
SHW
42
5
AES
47
4
FTI
61
5
DE
49
3
KMI
69
8
HCA
37
7
ROST
60
3
CRM
65
6
QRVO
16
-6
XYL
29
4
WBA
41
3
HCP
54
2
KO
44
2
NKE
36
2
CVX
25
14
ADP
57
2
FITB
36
3
HRB
40
3
ADI
54
4
Financhill
Back

Protalix BioTherapeutics 10K Form

Buy
68

PLX
Protalix BioTherapeutics

Last Price:
$1.76
Seasonality Move:
19.62%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLX News And Ratings

See the #1 stock for the next 7 days that we like better than PLX

PLX Financial Statistics

Sales & Book Value

Annual Sales: $65.5M
Cash Flow: $4M
Price / Cash Flow: 19.27
Annual Sales: $0.44
Price / Book: 4

Profitability

EPS (TTM): -0.16000
Net Income (TTM): $-9.6M
Gross Margin: $42.5M
Return on Equity: -29.54%
Return on Assets: -11.58%

Protalix BioTherapeutics Earnings Forecast

Key Protalix BioTherapeutics Financial Ratios

  • The Gross Profit Margin over the past 26 years for PLX is 64.91%.
  • The Selling, General & Administrative Expenses for PLX have been equal to 22.84% of Gross Profit Margin.
  • The Research & Development expenses have been 26.10% of Revenue.
  • The Interest Expense is 38.26% of Operating Income.
  • The Net Earning history of PLX is 12.69% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 13 years.

Protalix BioTherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: PLX
CUSIP: 74365A
Website: protalix.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.98
Quick Ratio: 1.22

Price-to-Earnings

Trailing P/E Ratio: 19.56
Forward P/E Ratio: 0

PLX Technical Analysis vs Fundamental Analysis

Buy
68
Protalix BioTherapeutics (PLX) is a Buy

Is Protalix BioTherapeutics a Buy or a Sell?